Karyopharm Therapeutics Company Profile (NASDAQ:KPTI)

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) released its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.64) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.64). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 70.42%. The company's quarterly revenue was down 95.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.84) EPS. View Karyopharm Therapeutics' Earnings History.

Karyopharm Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Karyopharm Therapeutics.

7 analysts have issued twelve-month price objectives for Karyopharm Therapeutics' shares. Their predictions range from $14.00 to $19.00. On average, they anticipate Karyopharm Therapeutics' stock price to reach $16.00 in the next year. View Analyst Ratings for Karyopharm Therapeutics.

Here are some recent quotes from research analysts about Karyopharm Therapeutics stock:

• 1. According to Zacks Investment Research, "Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. " (7/18/2017)
• 2. Cantor Fitzgerald analysts commented, "Support for KPTI’s DLBCL program (SADAL) could build with a presentation at the EHA (Abstract S469) in June." (5/15/2017)
• 3. HC Wainwright analysts commented, "Although selinexor is still technically on a partial clinical hold in the U.S., due to an omitted table in its most recent investigator's brochure, Karyopharm focused its 4Q call on the steady progress being made in its development across a range of indications. Having received its requested information, we believe the FDA should release the partial clinical hold well in advance of 4/9, and believe this hiccup will have no material impact on enrollment of the selinexor trials. On its call, Karyopharm noted that it had completed enrollment of its Phase 2/3 SEAL trial of selinexor in liposarcoma patients and expects to report topline data in mid-2017. While we do not currently include liposarcoma in our estimates, we note that selinexor had shown promising and durable stable disease outcomes in a Phase 1 study in sarcomas with a better PFS observed than the last prior regimen (19.4 v. 7.7 weeks) with 43% of liposarcoma patients achieving stable disease having a 4+ month response. Separately, Karyopharm provided updates on selinexor in multiple myeloma noting that the expanded STORM trial in penta-refractory myeloma patients was on track to read out in early-2018, the Phase 3 BOSTON trial was expected to start by April, and the Phase 1b/2 STOMP trial was to begin enrollment of a 44- patient Darzalex (daratumumab) combination arm, expected to read out in late-2017/early-2018. As of December, Karyopharm had a cash position of $175.5M, which the company believes sufficient to fund operations through 2018. In 2017, Karyopharm expects its cash burn to be $85-90M. We are maintaining our KPTI price target of $14, based on a sum-of-the-parts DCF consisting of $6 for selinexor in MM, $4 sel in DLBCL, and $4 cash." (3/17/2017)

Some companies that are related to Karyopharm Therapeutics include NeuroDerm (NDRM), REGENXBIO (RGNX), Xencor (XNCR), Epizyme (EPZM), Athenex (ATNX), Retrophin (RTRX), Amarin Corporation PLC (AMRN), Ignyta (RXDX), Reata Pharmaceuticals (RETA), Omeros Corporation (OMER), Cytokinetics, Incorporated (CYTK), Revance Therapeutics (RVNC), Alder BioPharmaceuticals (ALDR), Keryx Biopharmaceuticals (KERX), La Jolla Pharmaceutical Company (LJPC), ZIOPHARM Oncology (ZIOP), CytomX Therapeutics (CTMX) and Flexion Therapeutics (FLXN).

Karyopharm Therapeutics' management team includes the folowing people:

• Sharon Shacham Ph.D., President, Co-Founder, Chief Scientific Officer, Director
• Michael G. Kauffman M.D. Ph.D., Co-Founder, Chief Executive Officer and Director
• Michael Falvey, Chief Financial Officer, Executive Vice President, Treasurer, Principal Financial Officer, Principal Accounting Officer
• Michael J. Todisco CPA, Vice President - Finance, Assistant Treasurer
• Christopher B. Primiano, Vice President- Corporate Development, General Counsel, Secretary
• Dilara McCauley Ph.D., Vice President - Product Leadership
• Brian Austad Ph.D., Senior Director, Head - Pharmaceutical Sciences
• Ran Frenkel, Chief Development Operations Officer
• Barry E. Greene, Lead Independent Director
• Mikael Dolsten M.D., Ph.D., Director

Shares of Karyopharm Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Karyopharm Therapeutics stock can currently be purchased for approximately $10.97.